{"id":22608,"title":"Robust measurement of the real world effectiveness of Tofacitinib for the treatment of Ulcerative Colitis using electronic health records: a protocol and statistical analysis plan","title_html":"Robust measurement of the real world effectiveness of Tofacitinib for the treatment of Ulcerative Colitis using electronic health records: a protocol and statistical analysis plan","image":{"source":"https:\/\/www.protocols.io\/img\/default_protocol.png","placeholder":"https:\/\/www.protocols.io\/img\/default_protocol.png"},"doi":"dx.doi.org\/10.17504\/protocols.io.2bqgamw","doi_status":2,"uri":"robust-measurement-of-the-real-world-effectiveness-2bqgamw","type_id":1,"published_on":1558576264,"version_id":0,"created_on":1556155827,"categories":null,"creator":{"name":"Vivek A. Rudrapatna","affiliation":"University of California, San Francisco","affiliations":[{"affiliation":"University of California, San Francisco","url":"http:\/\/www.ucsf.edu","is_default":1}],"username":"vivek-rudrapatna","link":null,"image":{"source":"\/img\/avatars\/011.png","placeholder":"\/img\/avatars\/011.png"},"badges":[{"id":2,"image":{"source":"\/img\/badges\/bronze.svg","placeholder":"\/img\/badges\/bronze.svg"},"name":"Author"}],"research_interests":null},"journal":null,"journal_name":null,"journal_link":null,"article_citation":null,"public":1,"has_versions":0,"link":null,"total_collections":0,"number_of_steps":32,"authors":[{"name":"Vivek A. Rudrapatna","affiliation":"University of California, San Francisco","affiliations":[],"username":"vivek-rudrapatna","link":null,"image":{"source":"\/img\/avatars\/011.png","placeholder":"\/img\/avatars\/011.png"},"badges":[],"research_interests":null},{"name":"Atul J. Butte","affiliation":"University of California, San Francisco","affiliations":[],"username":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"research_interests":null}],"versions":[],"groups":[],"has_subprotocols":0,"is_subprotocol":0,"is_bookmarked":0,"can_be_copied":1,"can_remove_fork":1,"forks_count":{"private":0,"public":0},"access":{"can_view":1,"can_remove":0,"can_add":0,"can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":1,"can_move":1,"can_move_outside":1,"can_transfer":1,"can_download":1,"is_locked":0},"steps":[{"id":738273,"guid":"468977306DD011E995CCE1C53F573BF9","previous_id":null,"previous_guid":null,"modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"66338227B234475E96DB4133926732E0","order_id":1,"type_id":6,"title":"Section","source":{"title":"Validating prospective MRNs using the 'Received Tofacitinib' spreadsheet"}},{"id":1054724,"guid":"DB2B8C1CC90042009F5DA768E10C3E85","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Diagnosis<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{UC, CD, NA}<\/div><div class = \"text-block\">The best place to unambiguously identify a working diagnosis is a recent colonoscopy done near the time of treatment initiation. In particular, the indication, impression, and recommendations section are often quite useful. <\/div><div class = \"text-block\">Otherwise, use the diagnosis made at the GI encounter just preceding the prescription and initiation of the drug. This is often helpful because insurance prior authorization of a given medication often requires a clear diagnosis, which is documented in the clinic visit and sent to the payor. <\/div><div class = \"text-block\">Be mindful of the facts that: <\/div><div class = \"text-block\">1) the EHR can auto-populate the (sometimes incorrect) diagnosis at the very top and at the first line of the assessment and plan, and <\/div><div class = \"text-block\">2) copy-forwarded notes can obscure cases of a revised diagnosis (e.g. top of HPI states Ulcerative Colitis, and mid-way indicates Crohn\u2019s). <\/div><div class = \"text-block\">In the latter case, rely on what has been documented in the assessment and plan. <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738274,"guid":"669A63906DD011E995CCE1C53F573BF9","previous_id":738273,"previous_guid":"468977306DD011E995CCE1C53F573BF9","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"517BD4EC435347DF820445C4E76D8F7A","order_id":1,"type_id":6,"title":"Section","source":{"title":"Validating prospective MRNs using the 'Received Tofacitinib' spreadsheet"}},{"id":1054724,"guid":"FDD4D7EE8C424DF798B9EDA9959EBC5A","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Received Tofacitinib<\/span><span>: <\/span><\/div><div class = \"text-block\">{Y, N, NA}<\/div><div class = \"text-block\">In general, the presence of a medication order or renewal should be considered insufficient evidence that a drug has actually been taken by the patient. <\/div><div class = \"text-block\">The best evidence for this is a message from a patient indicating that they\u2019ve started the drug, or a telephone encounter documenting as such. These often yield precise dates of initiation. Reports from colonoscopies performed to assess treatment response can indicate the date or approximate date of start.<\/div><div class = \"text-block\">A sequence of clinic notes indicating plans to start the drug followed by a post-initiation visit or endoscopy assessing treatment response can be helpful too. Multiple independent notes from GIs and non-GIs suggesting that the patient started a treatment is good evidence supporting this.<\/div><div class = \"text-block\">If the above is unavailable, historical clinical documentation (notes from treating physicians, Indications\/Impression\/Recommendations sections from endoscopy reports) can be quite helpful.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738275,"guid":"80A283306DD011E995CCE1C53F573BF9","previous_id":738274,"previous_guid":"669A63906DD011E995CCE1C53F573BF9","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"3617626FAA844C119D93EE4E5937A017","order_id":1,"type_id":6,"title":"Section","source":{"title":"Validating prospective MRNs using the 'Received Tofacitinib' spreadsheet"}},{"id":1054724,"guid":"FA000BB611AB41E886E7B366E0E62C8E","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Initiated to treat IBD<\/span><span>: <\/span><\/div><div class = \"text-block\">{Y, N, NA}<\/div><div class = \"text-block\">Sometimes patients are initiated on Tofacitinib for reasons that are unrelated to Ulcerative Colitis (for instance, rheumatological or dermatological disorders).<\/div><div class = \"text-block\">Score as Y if the patient was given the drug for the purposes of treating Ulcerative Colitis (this would most often be decided and ordered by a gastroenterology provider)<\/div><div class = \"text-block\">Score as N if not. In the setting of UC, this should also include uncommon settings where patients had subtotal colectomies and are trying a steroid-sparing agent before proceeding with completion proctectomy (e.g. these are also scored as an N). Although this logically might be a scenario where one could still assess whether or not it is effective in treating inflammation, monitoring response to treatment is more complex and may not reflect the typical performance of this drug in the setting where it has been formally studied.<\/div><div class = \"text-block\"><span>If this is the case, these patients can be treated the same as those who did <\/span><span style = \"font-weight:bold;\">not<\/span><span> receive the medication; <\/span><span style = \":UNDERLINE;\">their MRNs should not be transferred to the Table 1 and Efficacy sheets<\/span><span> for further analysis (see subsequent sections).<\/span><\/div><div class = \"text-block\">For patients with active symptoms and minimal endoscopic IBD activity, if they were given IBD treatment in the hopes that their symptoms would improve (vs not improve because the symptoms were actually due to something else such as IBS\/SIBO), code this as a Y. <\/div><div class = \"text-block\">If the patient did not even receive the medication (as annotated by the prior variable), code as \u2018NA.\u2019<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738276,"guid":"869668606DD011E995CCE1C53F573BF9","previous_id":738275,"previous_guid":"80A283306DD011E995CCE1C53F573BF9","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"51A85F2DC50F4405BF258C1F5BA7FBD7","order_id":1,"type_id":6,"title":"Section","source":{"title":"Validating prospective MRNs using the 'Received Tofacitinib' spreadsheet"}},{"id":1054724,"guid":"9E912EDC32F444EC8D886ED83B7A783E","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\"> <\/span><span style = \"font-weight:bold;\">Inconsistent Use<\/span><span>:\n {Y, N, NA}\n  \nAnnotate as Y if there is evidence on chart review that the patient was not taking the medication regularly, for example due to personal preferences. Annotate N if no chart evidence to support this. Minimize the use of NA (e.g. if there is <\/span><span style = \":UNDERLINE;\">no<\/span><span> evidence that the patient was the drug inconsistently, annotate as N rather than NA).\n <\/span><\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738291,"guid":"9DBE6D506DE211E995CCE1C53F573BF9","previous_id":738276,"previous_guid":"869668606DD011E995CCE1C53F573BF9","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"17864B1156A64709B3CD13F8B7806AC5","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"F28C6949D8F4452787A254A246A64A33","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Gender<\/span><span>: <\/span><\/div><div class = \"text-block\">{M, F, NA}<\/div><div class = \"text-block\">As ascertained from the clinic note and the demographic face sheet. If there is any evidence of a mismatch (e.g. indicating error or sex-change), score as NA<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738292,"guid":"DEECD4106DE211E995CCE1C53F573BF9","previous_id":738291,"previous_guid":"9DBE6D506DE211E995CCE1C53F573BF9","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"24DA295A177D42A7B65BD932F1EF0A2F","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"A727C633DCBB4756943FACAADB756E36","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Date of Disease Onset<\/span><span>: <\/span><\/div><div class = \"text-block\">{YYYY-MM-DD, NA}<\/div><div class = \"text-block\"><span>Use a combination of the earliest notes in the system (use the <\/span><span style = \"font-style:italic;\">Notes<\/span><span> tab, not the <\/span><span style = \"font-style:italic;\">Encounter<\/span><span> tab), the <\/span><span style = \"font-style:italic;\">Scanned Clinical Documents <\/span><span>tab corresponding to the original clinic referral, and <\/span><span style = \"font-style:italic;\">Care Everywhere<\/span><span> in order to determine as precisely as possible when the patient\u2019s disease began. As above, round down for situations where only the month (e.g. 4\/1\/2018) or the year (1\/1\/2018) is known. When notes document age of onset rather than date of onset, can select the first day of the next month following the patients birthdate. For instance if the patient is born 2\/19\/84 and developed the diagnosis at age 10, annotate this as 3\/1\/94. <\/span><\/div><div class = \"text-block\">For Ulcerative Colitis, the timing of clearly attributable disease onset (rectal bleeding with tenesmus\/nocturnal symptoms\/weight loss) might have occurred prior to the time of colonoscopic diagnosis. Patients often recall a clear timepoint as to when their symptoms began but sometimes their symptom onset is unclear or not classic for IBD (increased stool frequency without other hallmarks of inflammatory diarrhea as above). In the event of the latter use the date of colonoscopic diagnosis.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738293,"guid":"5FD29C806DE411E995CCE1C53F573BF9","previous_id":738292,"previous_guid":"DEECD4106DE211E995CCE1C53F573BF9","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"44059CDBBFE34AD5BFA1A3345D995D45","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"24A06D77F7DC47BFB55877E1BB25CC1F","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Age at Tofacitinib initiation (in years, rounded down)<\/span><span>: <\/span><\/div><div class = \"text-block\">{Integer, NA}<\/div><div class = \"text-block\">To be calculated based on the patient\u2019s birthdate and the date of Tofacitinib initiation. Be wary of using the age reported in clinic notes as the basis of this \u2013 these notes are often copy-forwarded and incorrect. Use the birthdate and date of drug initiation.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738294,"guid":"F79DB9606DE811E995CCE1C53F573BF9","previous_id":742238,"previous_guid":"3D584750775211E9950C2D1F0043C634","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"FDF9CAA45631493D9C6889688355BE48","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"A04532A5765B49C88B58DF1E0677608C","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Disease extent at time of Tofacitinib initiation<\/span><span>: <\/span><\/div><div class = \"text-block\">{1, 2, 3, NA}<\/div><div class = \"text-block\">1 = Proctitis or Proctosigmoiditis<\/div><div class = \"text-block\">2 = Left-sided colitis (extends to but not beyond the splenic flexure<\/div><div class = \"text-block\">3 = Extensive or pan-ulcerative colitis (anything extending beyond the splenic flexure)<\/div><div class = \"text-block\">Prioritize Sigmoidoscopic\/Colonoscopic data prior to Tofacitinib initiation as the gold standard to ascertain this (e.g. how far the disease had spread by the time Tofa had started). This should reflect the extent of underlying anatomical territory that has ever been endoscopically involved up to this timepoint, not just what is currently involved (e.g. if the rectum appears spared on a follow-up exam and the patient is on treatments including steroid enemas this should not affect the categorization of the disease extent). <\/div><div class = \"text-block\"><span>If Sigmoidoscopy reveals disease through the extent of the exam, can also use supportive imaging data as needed to judge extent. If this is unavailable, acceptable to use note-based documentation.  <\/span><span style = \":UNDERLINE;\">Be aware that imaging-based extent can often overcall extent compared to endoscopy and histology<\/span><span>. <\/span><\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">Under scenarios of discrepant endoscopic findings (endoscopic extent involving the transverse colon in one and not in another), annotate this field by the maximum documented extent<\/span><span>. <\/span><\/div><div class = \"text-block\">It is acceptable to use data from within 6 months of the start to retroactively assess disease extent. For instance, if a clinic note indicates left-sided colitis but imaging and surgical pathology within 6 months indicate extensive\/pancolitis, annotate as the latter. The assumption is that sampling error and chronic disease progression is a more likely explanation for prior misclassification than the possibility that the drug caused an acute and significant extension of anatomic involvement). <\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">Score this based on endoscopic rather than histologic disease extent<\/span><span>. The rationale for this is that the disease extent classification in the trials was more likely to use gross endoscopic extent rather than histologic extent. This need not fall strictly within the same strict time windows as the Mayo Score data.<\/span><\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738295,"guid":"B465F8A06DE911E995CCE1C53F573BF9","previous_id":738294,"previous_guid":"F79DB9606DE811E995CCE1C53F573BF9","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"938C4A65CC5A48F4A1C56FEBE27D3CDD","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"228AA209EE234E55A16CBB10378C70A9","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Baseline Mayo stool frequency subscore<\/span><span>: <\/span><\/div><div class = \"text-block\">{0, 1, 2, 3, NA}<\/div><div class = \"text-block\"><span>We are attempting to capture this Mayo subscore within 6 months of the date of Tofacitinib initiation (e.g. <\/span><span style = \"font-weight:bold;\">Month -6 to Month 0<\/span><span>). The idea here is to attempt to match our patient cohort with that of the clinical trials.<\/span><\/div><div class = \"text-block\">The rationale for using such a broad time window is that endoscopic scheduling and insurance approval for a planned drug, among other factors, can create a lag between the time of Mayo endoscopic subscore data availability and treatment initiation. So we are allowing the other Mayo subscore variables to capture data from the same time window.<\/div><div class = \"text-block\">Per the OCTAVE supplemental data protocol (Appendix 1, page 80): <\/div><div class = \"text-block\">0: Normal number of bowel movements for this patient<\/div><div class = \"text-block\">1: 1 to 2 bowel movements more than normal<\/div><div class = \"text-block\">2: 3 to 4 bowel movements more than normal<\/div><div class = \"text-block\">3: 5 or more bowel movements more than normal<\/div><div class = \"text-block\"><span>The above data is sometimes documented in the chart by absolute frequency of bowel movements. Per FDA guidance a bowel movement \u201c<\/span><span style = \":UNDERLINE;\">is defined as a trip to the toilet when the patient has either a bowel movement, or passes blood alone, blood and mucus, or mucus only<\/span><span>.\u201d Therefore, <\/span><span style = \":UNDERLINE;\">stool frequency should incorporate toilet trips when there is passage of any liquid or solid content through the anus, not limited only to feces<\/span><span>.<\/span><\/div><div class = \"text-block\">If the stool frequency is reported as a relative increase over baseline, no ascertainment of absolute baseline frequency is required. However, if stool frequency is reported as an absolute frequency, the chart reviewer must make every effort to identify a baseline stool frequency from the chart. This can be identified from anywhere within full record, including timepoints before or after Tofacitinib use. We recommend using the global search functionality to look for keywords like: \u201cbaseline\u201d \u201cnormal\u201d \u201c1-2\u201d \u201c2-3\u201d \u201cstools\u201d \u201cbowel movements\u201d etc. <\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">If the notes do not explicitly mention \u201cbaseline\u201d but do indicate a stool frequency of between 1-3 bowel movements daily in any context (e.g. other treatments such as steroids), treat this number as the baseline<\/span><span>. The justification for this is that population-based studies have suggested that up to 3 bowel movements daily can be considered normal. <\/span><\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">If the patient has baseline constipation during periods of quiescence and returns to use of stool softeners\/laxatives, can impute this field to 0<\/span><span> (e.g. assume use of stool softeners to achieve 1 bowel movement daily).<\/span><\/div><div class = \"text-block\">If no \u201cbaseline\u201d nor approximate baseline is mentioned, a baseline of 3 bowel movements daily can be imputed at the chart reviewers discretion. This selection would not be expected to significantly affect the study results since the analysis will involve the paired differences in Mayo scores. If this is done an additional indicator variable denoting that this was performed should be added to the data collection spreadsheet.<\/div><div class = \"text-block\"><span>When dealing with numeric ranges of bowel movements, <\/span><span style = \":UNDERLINE;\">calculate the score based on the minimum increase in stool frequency compatible with the range<\/span><span>. For instance, if a patient has 1-2 bowel movements at baseline, and is currently having 5-6 during the morning and 2-3 over the rest of the day, this would be a difference between (1 to 2) and (7 to 9), corresponding to a minimum increase of 6 bowel movements above baseline (e.g. 1 to 7 is 6 above baseline, 2 to 9 is 7 above baseline, hence take the minimum). Therefore, this is scored as a \u20183\u2019 based on the above rubric.<\/span><\/div><div class = \"text-block\">In the event that multiple such subscores exist within this window, we use the following algorithm:<\/div><div class = \"text-block\"><ol style = \"list-style-type: decimal;\"><li style = \"counter-reset:ol0;\"> Select the stool frequency subscore occurring closest in time to the date of treatment failure<\/li><li style = \"counter-reset:ol0;\"> If no treatment failure and a colonoscopy was performed within this period, select the stool frequency subscore occurring closest in time to the date of the colonoscopy<\/li><li style = \"counter-reset:ol0;\"> If no colonoscopy was performed in this period, select the highest available subscore within this 6 month window.<\/li><\/ol><\/div><div class = \"text-block\">The rationale for picking the highest score within the window is that some assessments may be masked by concomitant therapy (e.g. steroids) which are somewhat harder to ascertain from the EHR. <\/div><div class = \"text-block\">As mentioned in the top section \u2018Guidelines\u2019: exclude any stool frequency confounded by the presence of a concomitant infection or treatment interruption. The exception to this rule is the presence of concomitant steroids. In this case, report the stool frequency; we will also capture the presence of steroid use in a separate indicator variable. <\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">Score this field as NA if it is not satisfactorily identified.<\/span><\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738331,"guid":"55E92B706DEA11E995CCE1C53F573BF9","previous_id":738295,"previous_guid":"B465F8A06DE911E995CCE1C53F573BF9","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"976C1ADCC2B248BE8CCD5B0FFF793DDA","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"E7E5E49500FB41FA850D9C5C4022B2F8","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Baseline<\/span><span style = \"font-weight:bold;font-weight:bold;\"> <\/span><span style = \"font-weight:bold;\">Mayo rectal bleeding subscore<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{0, 1, 2, 3, NA}<\/div><div class = \"text-block\"><span>We are attempting to capture this Mayo subscore within 6 months of the date of Tofacitinib initiation (e.g. <\/span><span style = \"font-weight:bold;\">Month -6 to Month 0<\/span><span>). The idea here is to attempt to match our patient cohort with that of the clinical trials.<\/span><\/div><div class = \"text-block\">The rationale for using such a broad time window is that endoscopic scheduling and insurance approval for a planned drug, among other factors, can create a lag between the time of Mayo endoscopic subscore data availability and treatment initiation. So we are allowing the other Mayo subscore variables to capture data from the same time window.<\/div><div class = \"text-block\">Per the OCTAVE supplemental data protocol (Appendix 1, page 80): <\/div><div class = \"text-block\">0: No blood seen<\/div><div class = \"text-block\">1: Streaks of blood with stool less than half the time<\/div><div class = \"text-block\">2: Obvious blood with stool most of the time<\/div><div class = \"text-block\">3: Blood alone passes<\/div><div class = \"text-block\"><span>This part of the score has been recognized by the FDA to be suboptimal (FDA CDER Draft Guidance, Aug 2016) for multiple reasons including the fact that it is a \u201cdouble-barreled\u201d question (e.g. asks about both amount and frequency of blood). Presumably as a measure to correct the frequency problem, the Pfizer Protocol indicates that this should be scored \u201c<\/span><span style = \":UNDERLINE;\">the most severe bleeding of the day<\/span><span>.\u201d<\/span><\/div><div class = \"text-block\">We have adopted the following pragmatic strategy: <\/div><div class = \"text-block\">1) If data of bleeding severity is available, then score based on this as follows: <\/div><div class = \"text-block\">    o If there is clear documentation of no bleeding, score as 0. <\/div><div class = \"text-block\">    o If there is clear documentation of episodes where only blood passes, score this as a 3. <\/div><div class = \"text-block\">    o If there is bleeding but the amount is vague (e.g. \u201csome\u201d) then code this as a 1.5. <\/div><div class = \"text-block\">    o Otherwise if there is a clear indication of degree of bleeding, use 1 or 2 as appropriate. <\/div><div class = \"text-block\">2) If severity data is not available but the frequency data is, then scoring using this data and the OCTAVE metric above can be performed at the discretion of the chart abstractor. <\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">If there exist multiple datapoints within this 6-month time window, use the approach as outlined in the stool frequency section<\/span><span>. <\/span><span style = \":UNDERLINE;\">If multiple datapoints around the same time suggest slightly different degrees of bleeding, select the most severe degree of bleeding<\/span><span>. <\/span><span style = \":UNDERLINE;\">If the note indicates blood 50% of the time, score as 1.5.<\/span><\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738341,"guid":"51B430206DF111E9B6950997FED07152","previous_id":738361,"previous_guid":"8AA152606E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"AA9115FFB37D4B058CD083F0C58888EF","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"3505C8251E964F6585FD30B10C62D80D","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Date of Tofacitinib initiation<\/span><span>: <\/span><\/div><div class = \"text-block\">{YYYY-MM-DD, NA}<\/div><div class = \"text-block\">As above, the best evidence to ascertain this is a message from a patient indicating that they\u2019ve started the drug, or a telephone encounter documenting as such. These often give relatively precise dates of initiation.<\/div><div class = \"text-block\">If there is a sequence of clinical notes (before and after) that are consistent with initiation, these can be used in combination with the date of medication orders (listed within a medication order) to find a more precise date of initiation. <\/div><div class = \"text-block\">If dealing with older notes where supporting data (e.g. patient messages, medication orders) are unavailable, then document use the month (or less commonly, the year) and report a \u201crounded down\u201d date (e.g. 2018-05-01).<\/div><div class = \"text-block\">Rarely, there are patients who have been on a drug for multiple continuous periods of time (e.g. initially on a clinical trial then again later, or patients who stop due to possible drug reaction and subsequently restart). In these scenarios, prioritize the longest period of sustained use. If there are multiple, equally long on-off periods, select the most recent period with well-defined start and end dates. If this is not possible because the patient starts and stops a drug erratically or does not use it daily, score this as NA and annotate the \u201cinconsistent use\u201d column accordingly.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738342,"guid":"B9E3FB706DF211E9B6950997FED07152","previous_id":738341,"previous_guid":"51B430206DF111E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"2423D01816F04963BFACB86F098F9070","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"FD744A09C5D745B087D5473F858E4EC5","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Date of last known use of Tofacitinib (date of censorship)<\/span><\/div><div class = \"text-block\">{YYYY-MM-DD, NA}<\/div><div class = \"text-block\">This date corresponds to the last observed date that the drug was observed being used (from the standpoint of survival analysis). This could be the date of discontinuation, the last date of any available evidence (e.g. contact with our clinic or other accessible gastroenterologists), date of surgery, or date of death. If patients are still on the drug as of the date of the record review, this would be the recorded date (and they would be considered administratively censored).<\/div><div class = \"text-block\">As before, the best evidence to get this comes from a patient email indicating that they\u2019ve stopped the drug, a colonoscopy report with the recommendation to stop the treatment given futility, or a clinician writing to a patient indicating to a patient that they should stop the drug. <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738343,"guid":"2222B0506DF311E9B6950997FED07152","previous_id":738342,"previous_guid":"B9E3FB706DF211E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"9591705441984DFAB47C273B4816A7EB","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"1C8D8098D4ED4A1783C999893C17B85F","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Status at date of last use (censorship status)<\/span><\/div><div class = \"text-block\">{0, 1, 2, 3, NA}<\/div><div class = \"text-block\">Score as 1 if the treatment has been deemed futile. This could be for any reason \u2013 lack of effectiveness or adverse outcome\/intolerance. This could be decided by either the patient or the physician (or both).<\/div><div class = \"text-block\">Score as 0 (administratively censored) if the \u2018implicit\/true time of treatment failure\u2019 is longer than the time under observation. For instance, if the patient is still on a drug as of the date of a chart review, or the patient discontinues the drug due to loss of insurance coverage, their latent \u2018survival\u2019 time is longer than the time under observation (e.g. under different circumstances with greater observation time and guaranteed insurance, the measured time to treatment failure would be longer than what was measured here). Here, the loss of insurance coverage is being treated as MCAR (missing completely at random). <\/div><div class = \"text-block\"><span>Score as a 2 if the patient was lost to follow-up defined as the absence of any data relevant to IBD status and continued treatment anywhere in the chart (including <\/span><span style = \"font-style:italic;\">Care Everywhere<\/span><span>) for 1 year. This category is a stand in for any status where the investigator must assess on a case by case basis whether the event can be justifiably be understood as resulting in data MCAR vs other types of missingness.<\/span><\/div><div class = \"text-block\">Score as 3 if the patient underwent a true competing event (e.g. all-cause mortality) that fundamentally precludes the observation of interest (e.g. treatment survival time).<\/div><div class = \"text-block\">If a patient undergoes surgery because a treatment is deemed a failure, score this as a 1. If the patient undergoes surgery due to longstanding fibrostenotic strictures and the drug is not resumed after surgery (with notes suggesting the absence of evidence that the treatment was a failure), score this as a 0.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738344,"guid":"747891D06DF311E9B6950997FED07152","previous_id":738343,"previous_guid":"2222B0506DF311E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"7B5DA8E9CCF44E78AA1D39192F2BBB16","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"8397A89E54D2479CB75AF074316DA46A","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Follow-up Mayo stool frequency subscore<\/span><span>: <\/span><\/div><div class = \"text-block\">{0, 1, 2, 3, NA}<\/div><div class = \"text-block\"><span>We are collecting the components of the Mayo score in order to allow us to closely mimic the primary endpoints of the OCTAVE trials. These endpoints are intended to measure the proportion of patients who respond to maintenance therapy at the 1 year time point. At our institution we do not protocolize the timing of clinic follow-up and different clinicians have different practices. However, many clinicians tend to formal assess response to therapy by month ~3 for Ulcerative Colitis, and occasionally month ~4-6 especially in individuals who have shown partial benefit within the first few months. However, scheduling in routine clinical contexts can be imprecise. Many patients live far away, sometimes in other states. Due to these considerations, including personal and administrative delays in scheduling, insurance approval etc., we are collecting the stool frequency subscore <\/span><span style = \"font-style:italic;\">within the window from month 2 through to month 8 after treatment initiation.<\/span><\/div><div class = \"text-block\">We considered a longer follow-up time to more closely mimic the 1 year time point studied in OCTAVE Sustain but pilot studies suggested that endoscopic and clinical assessment at that time was less common than at earlier time points (and therefore might result in more missing data).<\/div><div class = \"text-block\">Per the OCTAVE supplemental data protocol (Appendix 1, page 80), this subscore is to be scored using the following ordinal scale:<\/div><div class = \"text-block\">0: Normal number of bowel movements for this patient<\/div><div class = \"text-block\">1: 1 to 2 bowel movements more than normal<\/div><div class = \"text-block\">2: 3 to 4 bowel movements more than normal<\/div><div class = \"text-block\">3: 5 or more bowel movements more than normal<\/div><div class = \"text-block\"><span>Per FDA guidance a bowel movement \u201cis defined as a trip to the toilet when the patient has either a bowel movement, or passes blood alone, blood and mucus, or mucus only.\u201d Therefore, <\/span><span style = \":UNDERLINE;\">stool frequency should incorporate toilet trips when there is passage of any liquid or solid content through the anus, not limited only to feces<\/span><span>.<\/span><\/div><div class = \"text-block\">If the stool frequency is reported as a relative increase over baseline, no ascertainment of absolute baseline frequency is required. However, if stool frequency is reported as an absolute frequency, the chart reviewer must make every effort to identify a baseline stool frequency from the chart. This can be identified from anywhere within full record, including timepoints before or after Tofacitinib use. We recommend using the global search functionality to look for keywords like: \u201cbaseline\u201d \u201cnormal\u201d \u201c1-2\u201d \u201c2-3\u201d \u201cstools\u201d \u201cbowel movements\u201d etc. <\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">If the notes do not explicitly mention \u201cbaseline\u201d but do indicate a stool frequency of between 1-3 bowel movements daily in any context (e.g. other treatments such as steroids), treat this number as the baseline<\/span><span>. The justification for this is that population-based studies have suggested that up to 3 bowel movements daily can be considered normal. <\/span><\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">If the patient has baseline constipation during periods of quiescence and returns to use of stool softeners\/laxatives, can impute this field to 0<\/span><span> (e.g. assume use of stool softeners to achieve 1 bowel movement daily).<\/span><\/div><div class = \"text-block\">If no \u201cbaseline\u201d nor approximate baseline is mentioned, a baseline of 3 bowel movements daily can be imputed at the chart reviewers discretion. This selection would not be expected to significantly affect the study results since the analysis will involve the paired differences in Mayo scores. If this is done an additional indicator variable denoting that this was performed should be added to the data collection spreadsheet.<\/div><div class = \"text-block\"><span>When dealing with numeric ranges of bowel movements, <\/span><span style = \":UNDERLINE;\">calculate the score based on the minimum increase in stool frequency compatible with the range<\/span><span>. For instance, if a patient has 1-2 bowel movements at baseline, and is currently having 5-6 during the morning and 2-3 over the rest of the day, this would be a difference between (1 to 2) and (7 to 9), corresponding to a minimum increase of 6 bowel movements above baseline (e.g. 1 to 7 is 6 above baseline, 2 to 9 is 7 above baseline, hence take the minimum). Therefore, this is scored as a \u20183\u2019 based on the above rubric.<\/span><\/div><div class = \"text-block\">In the event that multiple such subscores exist within this window, we use the following algorithm:<\/div><div class = \"text-block\"><ol style = \"list-style-type: decimal;\"><li style = \"counter-reset:ol0;\"> Select the stool frequency subscore occurring closest in time to the date of treatment failure<\/li><li style = \"counter-reset:ol0;\"> If no treatment failure and a colonoscopy was performed within this period, select the stool frequency subscore occurring closest in time to the date of the colonoscopy<\/li><li style = \"counter-reset:ol0;\"> If no colonoscopy was performed in this period, select the highest available subscore within this 6 month window.<\/li><\/ol><\/div><div class = \"text-block\">The rationale for picking the highest score within the window is that some assessments may be masked by concomitant therapy (e.g. steroids) which are somewhat harder to ascertain from the EHR. <\/div><div class = \"text-block\">As mentioned in the top section \u2018Guidelines\u2019: exclude any stool frequency confounded by the presence of a concomitant infection or treatment interruption. The exception to this rule is the presence of concomitant steroids. In this case, report the stool frequency; we will also capture the presence of steroid use in a separate indicator variable. <\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">Score this field as NA if it is not satisfactorily identified.<\/span><\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738345,"guid":"8CD23E206DF311E9B6950997FED07152","previous_id":738344,"previous_guid":"747891D06DF311E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"FF7B3A64DEBC4672A09B114BFA1DAE8F","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"149EEDAA518E4EB39C6BFFA9F3FF32E4","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Follow-up<\/span><span style = \"font-weight:bold;font-weight:bold;\"> <\/span><span style = \"font-weight:bold;\">Mayo rectal bleeding subscore<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{0, 1, 2, 3, NA}<\/div><div class = \"text-block\"><span>We are collecting the components of the Mayo score in order to allow us to closely mimic the primary endpoints of the OCTAVE trials. These endpoints are intended to measure the proportion of patients who respond to maintenance therapy at the 1 year time point. At our institution we do not protocolize the timing of clinic follow-up and different clinicians have different practices. However, many clinicians tend to formal assess response to therapy by month ~3 for Ulcerative Colitis, and occasionally month ~4-6 especially in individuals who have shown partial benefit within the first few months. However, scheduling in routine clinical contexts can be imprecise. Many patients live far away, sometimes in other states. Due to these considerations, including personal and administrative delays in scheduling, insurance approval etc., we are collecting the rectal bleeding subscore <\/span><span style = \"font-style:italic;\">within the window from month 2 through to month 8 after treatment initiation.<\/span><\/div><div class = \"text-block\">We considered a longer follow-up time to more closely mimic the 1 year time point studied in OCTAVE Sustain but pilot studies suggested that endoscopic and clinical assessment at that time was less common than at earlier time points (and therefore might result in more missing data).<\/div><div class = \"text-block\">Per the OCTAVE supplemental data protocol (Appendix 1, page 80): <\/div><div class = \"text-block\">0: No blood seen<\/div><div class = \"text-block\">1: Streaks of blood with stool less than half the time<\/div><div class = \"text-block\">2: Obvious blood with stool most of the time<\/div><div class = \"text-block\">3: Blood alone passes<\/div><div class = \"text-block\">This subscore has been acknowledged by the FDA to be imperfect (FDA CDER Draft Guidance, Aug 2016) for multiple reasons including the fact that it is a \u201cdouble-barreled\u201d question (e.g. simultaneously assesses both amount and frequency of blood). Presumably as a measure to correct the frequency problem, the Pfizer protocol indicates that this should be scored based on \u201cthe most severe bleeding of the day.\u201d<\/div><div class = \"text-block\">We have adopted the following pragmatic strategy: <\/div><div class = \"text-block\">1) If data of bleeding severity is available, then score based on this as follows: <\/div><div class = \"text-block\">    o If there is clear documentation of no bleeding, score as 0. <\/div><div class = \"text-block\">    o If there is clear documentation of episodes where only blood passes, score this as a 3. <\/div><div class = \"text-block\">    o If there is bleeding but the amount is vague (e.g. \u201csome\u201d) then code this as a 1.5. <\/div><div class = \"text-block\">    o Otherwise if there is a clear indication of degree of bleeding, use 1 or 2 as appropriate. <\/div><div class = \"text-block\">2) If severity data is not available but the frequency data is, then scoring using this data and the OCTAVE metric above can be performed at the discretion of the chart abstractor. <\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">If there exist multiple datapoints within this 6-month time window, use the approach as outlined in the stool frequency section<\/span><span>. <\/span><span style = \":UNDERLINE;\">If multiple datapoints around the same time suggest slightly different degrees of bleeding, select the most severe degree of bleeding<\/span><span>. <\/span><span style = \":UNDERLINE;\">If the note indicates blood 50% of the time, score as 1.5.<\/span><\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738346,"guid":"9B8473206DF311E9B6950997FED07152","previous_id":738345,"previous_guid":"8CD23E206DF311E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"3D4621A660AB41C48C25A3F752A011FA","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"F42222B473AF440D8F609B0935402BB5","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Follow-up<\/span><span style = \"font-weight:bold;font-weight:bold;\"> <\/span><span style = \"font-weight:bold;\">Mayo PGA subscore<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{0, 1, 2, 3, NA}<\/div><div class = \"text-block\"><span>We are collecting the components of the Mayo score in order to allow us to closely mimic the primary endpoints of the OCTAVE trials. These endpoints are intended to measure the proportion of patients who respond to maintenance therapy at the 1 year time point. At our institution we do not protocolize the timing of clinic follow-up and different clinicians have different practices. However, many clinicians tend to formal assess response to therapy by month ~3 for Ulcerative Colitis, and occasionally month ~4-6 especially in individuals who have shown partial benefit within the first few months. However, scheduling in routine clinical contexts can be imprecise. Many patients live far away, sometimes in other states. Due to these considerations, including personal and administrative delays in scheduling, insurance approval etc., we are collecting the physician\u2019s global assessment within the window <\/span><span style = \"font-style:italic;\">from month 2 through to month 8 after treatment initiation.<\/span><span><\/span><\/div><div class = \"text-block\">We considered a longer follow-up time to more closely mimic the 1 year time point studied in OCTAVE Sustain but pilot studies suggested that endoscopic and clinical assessment at that time was less common than at earlier time points (and therefore might result in more missing data).<\/div><div class = \"text-block\">The scoring system is as follows (with acceptable phrasing in parenthesis): <\/div><div class = \"text-block\">0: Normal (\u201cin remission\u201d, \u201cin clinical remission\u201d)<\/div><div class = \"text-block\">1: Mild disease<\/div><div class = \"text-block\">2: Moderate disease<\/div><div class = \"text-block\">3: Severe disease<\/div><div class = \"text-block\">Per the Pfizer protocol used for the OCTAVE trials, this score \u201cacknowledges the three other criteria, the patient\u2019s recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the patient\u2019s performance status.\u201d<\/div><div class = \"text-block\"><span>This score ideally should reflect a <\/span><span style = \"font-weight:bold;\">dynamic<\/span><span>, \"real-time\" assessment of disease activity (e.g. evidence of ongoing inflammation cauing symptoms that is in principle modifiable by medication). This is in contrast to annotations of severe disease based on, for example, the history of multiple prior treatment failures. <\/span><\/div><div class = \"text-block\">A good place to identify the physician's global assessment (PGA) is the end of colonoscopy reports, where patients are commonly characterized as \"mild\" or \"severe\" independent of scoring using the Mayo endoscopic score. Other sources of the PGA include the Assessment and Plan of clinic notes, or appeal letters to insurance; the former is preferrable because it 1) is written by the attending physician, rather than fellows\/residents in clinic, and 2) appeal letters to insurance  may be at risk of bias.<\/div><div class = \"text-block\">In the event that multiple such subscores exist within this window, use the same approach as detailed in the stool frequency section.<\/div><div class = \"text-block\">As mentioned in the top section \u2018Guidelines\u2019: exclude any stool frequency confounded by the presence of a concomitant infection or treatment interruption. The exception to this rule is the presence of concomitant steroids. In this case, report the stool frequency; we will also capture the presence of steroid use in a separate indicator variable. <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738347,"guid":"A8E76BD06DF311E9B6950997FED07152","previous_id":738346,"previous_guid":"9B8473206DF311E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"1C497E15473241A3BDF60584881309A8","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"76FEC48EC7D7473C8E2D2DBA7E68C88A","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Follow-up Mayo endoscopic subcore<\/span><\/div><div class = \"text-block\">{0, 1, 2, 3, NA}<\/div><div class = \"text-block\"><span>We are collecting the components of the Mayo score in order to allow us to closely mimic the primary endpoints of the OCTAVE trials. These endpoints are intended to measure the proportion of patients who respond to maintenance therapy at the 1 year time point. At our institution we do not protocolize the timing of clinic follow-up and different clinicians have different practices. However, many clinicians tend to formal assess response to therapy by month ~3 for Ulcerative Colitis, and occasionally month ~4-6 especially in individuals who have shown partial benefit within the first few months. However, scheduling in routine clinical contexts can be imprecise. Many patients live far away, sometimes in other states. Due to these considerations, including personal and administrative delays in scheduling, insurance approval etc., we are collecting the endoscopic subscore within the window <\/span><span style = \"font-style:italic;\">from month 2 through to month 8 after treatment initiation.<\/span><\/div><div class = \"text-block\">We considered a longer follow-up time to more closely mimic the 1 year time point studied in OCTAVE Sustain but pilot studies suggested that endoscopic and clinical assessment at that time was less common than at earlier time points (and therefore might result in more missing data).<\/div><div class = \"text-block\"><span>Use the endoscopic impression of disease, and do not use any histological data to make this annotation. It is important to try to score this as the endoscopist would have scored it without introducing your own interpretation. Some endoscopists use a formal scoring system built into Endopro, whereas others use descriptive language to characterize the severity of the disease. In the event of the latter, use the words mapping to the <\/span><span style = \"font-weight:bold;\">most<\/span><span>severe endoscopic category to make your annotation.<\/span><\/div><div class = \"text-block\">Per the Supplemental Data form, use the modified Mayo endoscopic subscore as defined below. The unique terms that distinguish one category from another are underlined.<\/div><div class = \"text-block\"><span>0: Normal or <\/span><span style = \":UNDERLINE;\">inactive<\/span><span> disease (this includes chronic scaring, pseudopolyps)<\/span><\/div><div class = \"text-block\">1: Mild disease -- erythema, decreased vascular pattern<\/div><div class = \"text-block\"><span>2: Moderate disease -- marked erythema, lack of vascularity, <\/span><span style = \":UNDERLINE;\">any friability<\/span><span>, <\/span><span style = \":UNDERLINE;\">erosions<\/span><\/div><div class = \"text-block\"><span>3: Severe disease \u2013 <\/span><span style = \":UNDERLINE;\">spontaneous bleeding<\/span><span>, <\/span><span style = \":UNDERLINE;\">ulceration<\/span><span>(ulcers are defined by the presence of granulation tissue)<\/span><\/div><div class = \"text-block\">If there exist multiple datapoints within this time window, select the latest one up to the time of treatment failure, if it occurred.<\/div><div class = \"text-block\">If the patient is subsequently found to have superinfection including CMV that may influence the results of the endoscopy, consider excluding these results from the data used to annotate this field. <\/div><div class = \"text-block\">If the patient is on any glucocorticoid at the time this assessment is done, it\u2019s okay to report whatever was found here (as opposed to mark as \u2018NA\u2019); we are separately assessing corticosteroid use in a different variable. <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738352,"guid":"40BD82006DF411E9B6950997FED07152","previous_id":738366,"previous_guid":"EC8215A06E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"55234B6C53304AEC81FDD6A9E675109E","order_id":1,"type_id":6,"title":"Section","source":{"title":"Statistical Analysis Plan"}},{"id":1054724,"guid":"76063EE67E3C4CCBBEC4AE81E27FEF87","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Primary endpoints<\/span><span>: <\/span><\/div><div class = \"text-block\">1) Time to treatment failure<\/div><div class = \"text-block\"><span>2) Proportion of patients without treatment failure at 1 year (<\/span><span style = \"font-style:italic;\">real-world effectiveness rate<\/span><span style = \"font-style:italic;\">)<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Null hypothesis<\/span><span>: The probability of incident users of Tofacitinib without treatment failure at 1 year in the 'real-world' setting is equal to the probability of remission (total Mayo score of \u22642, with no subscore >1 and a rectal bleeding subscore of 0) at week 52 as reported by the OCTAVE investigators (Sandborn et al. 2017)<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Alternative hypothesis<\/span><span>: The probability of incident users of Tofacitinib without treatment failure at 1 year in the 'real-world' setting is <\/span><span style = \"font-weight:bold;\">not<\/span><span style = \"font-weight:bold;font-weight:bold;\"> <\/span><span style = \"font-weight:bold;\">equal<\/span><span> to the probability of remission (total Mayo score of \u22642, with no subscore >1 and a rectal bleeding subscore of 0) at week 52 as reported by the OCTAVE investigators (Sandborn et al. 2017)<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Sample size considerations<\/span><span>: Because this represents a uncontrolled study of observational data, no power calculation was performed. Preliminary data at our institution (UCSF) as of May 2019 suggested up to ~120 IBD patients who had been prescribed Tofacitinib.<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Analysis of primary endpoints<\/span><span>: <\/span><\/div><div class = \"text-block\">The time to treatment failure will be estimated using the Kaplan-Meier estimator; survival times corresponding to the 25th, 50th, and 75th percentiles of treatment failure will be calculated.<\/div><div class = \"text-block\">The analysis set will be restricted to individuals who individuals with observation time \u2265 1 year, and the counts of individuals with and without treatment failure at 1 year will be tabulated.<\/div><div class = \"text-block\"><span>Counts corresponding to Sandborn et al. 2017 will be computed as follows: The total proportion of responders will be calculated as the product of the probability of achieving <\/span><span style = \"font-style:italic;\">clinical response<\/span><span> (a decrease from baseline in Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1) at week 8 by the probability of achieving <\/span><span style = \"font-style:italic;\">remission<\/span><span> at week 52. The total number of patients assigned to the active arm of OCTAVE Sustain who achieved remission at week 52 will be divided by the aforementioned product to determine an effective sample size for the week 52 assessment of clincal remission. <\/span><\/div><div class = \"text-block\">These counts will be used to perform a Fisher's exact test.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Analysis of patient demographics<\/span><span>: <\/span><\/div><div class = \"text-block\">Patients with greater with observation time \u2265 1 year will be tabulated by baseline demographic characteristics measured here and compared to the summary statistics reported in Table 1 of Sandborn et al. 2017. Proportions and categorical variables will be compared by Fisher's exact test, means will be compared by 1-sample t-test, and medians compared by 1-sample Wilcoxon test. No corrections for multiple testing will be performed unless otherwise specified.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Quality Control<\/span><span>: Exploratory data analysis will be performed to confirm accuracy of data entry and identify outlying observations.<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Missing data<\/span><span>: Missing data will be handled by Multiple Imputation using Chained Equations using the Fully Conditional Specification using at least 20 chains and 10 interations. The quality of the imputations will be assessed via assessment of Markov Chain Monte Carlo trace plots and univariate and bivariate distributions of imputed values. Results will be assessed using different imputation models .<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Software<\/span><span>: All analyses will be performed in the <\/span><span style = \"font-style:italic;\">R<\/span><span> programming environment with the following packages representing a non-exclusive list: 'data.table', 'survival', 'survminer', 'readxl', 'tidyverse', 'scales', 'binom', 'ggplot2', 'lubridate', 'RMarkdown', 'MICE', 'caret'<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Sensitivity analysis<\/span><span>: <\/span><\/div><div class = \"text-block\">1) The hypothesis test comparing the real-world effectiveness rate with that of the OCTAVE Sustain trial will be repeated using less stringent W52 endpoints to account for the possibility that the real-world determination of treatment failure may be less stringent than that of the OCTAVE primary endpoint.<\/div><div class = \"text-block\">2) The data will be analyzed in a Bayesian framework with posterior probability distributions calculated using the following prior Beta distributions: Jeffrey's Prior, prior distribution corresponding to the patient counts from the OCTAVE Sustain trial, and a beta distribution with median equal to 1\/3 and 0.05 quantile equal to 0.1.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Exploratory analyses\/endpoints<\/span><span>: An exploratory analysis will include the following: <\/span><\/div><div class = \"text-block\">1) Proportion of real-world patients who would have qualified for the randomized clinical trial based on all Inclusion\/Exclusion criteria<\/div><div class = \"text-block\">2) Proportion of real-world patients who would have qualified for the randomized clinical trial based on baseline total Mayo Score<\/div><div class = \"text-block\">3) Proportion of real-world patients meeting the primary endpoint of clinical remission and selected secondary endpoints as defined and published by the OCTAVE investigators<\/div><div class = \"text-block\">4) Other machine learning algorithms (Random Forests, Support Vector Machines, Quadratic Discriminant Analysis, Ensemble Models, penalized logistic regression) will be explored to determine their accuracy in predicting treatment response using baseline and early follow-up covariates<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738353,"guid":"432092C06E0911E9B6950997FED07152","previous_id":738331,"previous_guid":"55E92B706DEA11E995CCE1C53F573BF9","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"DE545418527444DB809514E8AAC0518E","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"6612215172CC4C21AC1285F044ACE8C0","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Baseline Mayo PGA subscore<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{0, 1, 2, 3, NA}<\/div><div class = \"text-block\"><span>We are attempting to capture this Mayo subscore within 6 months of the date of Tofacitinib initiation (e.g. <\/span><span style = \"font-weight:bold;\">Month -6 to Month 0<\/span><span>). The idea here is to attempt to match our patient cohort with that of the clinical trials.<\/span><\/div><div class = \"text-block\">The rationale for using such a broad time window is that endoscopic scheduling and insurance approval for a planned drug, among other factors, can create a lag between the time of Mayo endoscopic subscore data availability and treatment initiation. So we are allowing the other Mayo subscore variables to capture data from the same time window.<\/div><div class = \"text-block\">Per the supplemental data: <\/div><div class = \"text-block\">0: Normal<\/div><div class = \"text-block\">1: Mild disease<\/div><div class = \"text-block\">2: Moderate disease<\/div><div class = \"text-block\">3: Severe disease<\/div><div class = \"text-block\">Per the Pfizer protocol used for the OCTAVE trials, this score \u201cacknowledges the three other criteria, the patient\u2019s recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the patient\u2019s performance status.\u201d<\/div><div class = \"text-block\"><span>This score ideally should reflect a <\/span><span style = \"font-weight:bold;\">dynamic<\/span><span>, \"real-time\" assessment of disease activity (e.g. evidence of ongoing inflammation cauing symptoms that is in principle modifiable by medication). This is in contrast to annotations of severe disease based on, for example, the history of multiple prior treatment failures. <\/span><\/div><div class = \"text-block\">A good place to identify the physician's global assessment (PGA) is the end of colonoscopy reports, where patients are commonly characterized as \"mild\" or \"severe\" independent of scoring using the Mayo endoscopic score. Other sources of the PGA include the Assessment and Plan of clinic notes, or appeal letters to insurance; the former is preferrable because it 1) is written by the attending physician, rather than fellows\/residents in clinic, and 2) appeal letters to insurance  may be at risk of bias.<\/div><div class = \"text-block\">In the event that multiple such subscores exist within this window, use the same approach as detailed in the stool frequency section.<\/div><div class = \"text-block\">As mentioned in the top section \u2018Guidelines\u2019: exclude any stool frequency confounded by the presence of a concomitant infection or treatment interruption. The exception to this rule is the presence of concomitant steroids. In this case, report the stool frequency; we will also capture the presence of steroid use in a separate indicator variable. <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738354,"guid":"4F5B86306E0911E9B6950997FED07152","previous_id":738353,"previous_guid":"432092C06E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"48BD81D80143450F9D0AE4BAE45E16F9","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"16C07ED18A554A9A9622006397E20F63","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Baseline Mayo endoscopic subscore<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{0, 1, 2, 3, NA}<\/div><div class = \"text-block\"><span>We are attempting to capture this Mayo subscore within 6 months of the date of Tofacitinib initiation (e.g. <\/span><span style = \"font-weight:bold;\">Month -6 to Month 0<\/span><span>). The idea here is to capture the severity of disease as well as the fact that this data was actively used to guide the decision to initiate Tofacitinib. Unlike the OCTAVE trials which required a staging colonoscopy to be performed within 1 week of randomization, we allow a 6 month lag here to account for delays in insurance approval and initiation. <\/span><\/div><div class = \"text-block\"><span>Use the endoscopic impression of disease \u2013 histological data can be supportive but in the trials the primary ascertainment was by centrally-read endoscopy alone. If the endoscopist explicitly reports a Mayo endoscopic subscore than report this in the field. If he or she does not, score it using the descriptive language from the report as they map to the fields below, and annotate <\/span><span style = \":UNDERLINE;\">based on the most severely affected segment<\/span><span>. If the colon was mostly quiet but there was an ulcer in the rectum, this would be scored as a 3.<\/span><\/div><div class = \"text-block\">Per the OCTAVE supplemental data protocol (Appendix 1, page 80), the modified Mayo endoscopic subscore as defined below. Underlined items and in parenthesis are my emphasis to facilitate distinguishing categories.<\/div><div class = \"text-block\"><span>0: Normal or <\/span><span style = \":UNDERLINE;\">inactive<\/span><span> disease (this includes chronic scaring, pseudopolyps)<\/span><\/div><div class = \"text-block\">1: Mild disease -- erythema, decreased vascular pattern<\/div><div class = \"text-block\"><span>2: Moderate disease -- marked erythema, lack of vascularity, <\/span><span style = \":UNDERLINE;\">any friability<\/span><span>, <\/span><span style = \":UNDERLINE;\">erosions<\/span><\/div><div class = \"text-block\"><span>3: Severe disease \u2013 <\/span><span style = \":UNDERLINE;\">spontaneous bleeding<\/span><span>, <\/span><span style = \":UNDERLINE;\">ulceration<\/span><span>(ulcers are defined by the presence of granulation tissue)<\/span><\/div><div class = \"text-block\">If there exist multiple datapoints within this time window, select the latest one up to the time of treatment failure, if it occurred.<\/div><div class = \"text-block\">If the patient is subsequently found to have superinfection including CMV that may influence the results of the endoscopy, consider excluding these results from the data used to annotate this field. <\/div><div class = \"text-block\">If the patient is on any glucocorticoid at the time this assessment is done, it\u2019s okay to report whatever was found here (as opposed to mark as \u2018NA\u2019); we are separately assessing corticosteroid use in a different variable. <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738355,"guid":"5093DF206E0911E9B6950997FED07152","previous_id":738354,"previous_guid":"4F5B86306E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"35AAFC1750894EAD9377E109F48D4749","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"9CE582EE248747128AC632D35A02C46E","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Baseline c-reactive protein<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{Rational number, NA}<\/div><div class = \"text-block\"><span>As with the Mayo Endoscopic subscore, use the latest available C-Reactive Protein within the 6 months preceding the date of Tofacitinib initiation. <\/span><span style = \":UNDERLINE;\">Please use the date of the lab draw to make your assessment<\/span><span>. If it is unavailable strictly within this 6 month antecedent window, score as NA. If the lab is reported under the quantifiable limit, report \u20180\u2019. If it is over the quantifiable limit, report the threshold of quantification.<\/span><\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">Be careful that different labs use different units<\/span><span>! All values should be reported in mg\/L, not mg\/dL.<\/span><\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738356,"guid":"51B6DB506E0911E9B6950997FED07152","previous_id":738355,"previous_guid":"5093DF206E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"CD1B21743E52443E855482ACA5BD6B38","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"C6B7FD2A73914078BC6C3DBC4AC9EC74","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Baseline fecal calprotectin<\/span><span>: <\/span><\/div><div class = \"text-block\">{Rational number, NA}<\/div><div class = \"text-block\"><span>As with the Mayo Endoscopic subscore, use the latest available Fecal Calprotectin within the 6 months preceding the date of Tofacitinib initiation. <\/span><span style = \":UNDERLINE;\">Please use the date of the lab draw to make your assessment<\/span><span>. If it is unavailable strictly within this 6 month antecedent window, score as NA. If the lab is reported under the quantifiable limit, report \u20180\u2019. If it is over the quantifiable limit, report the threshold of quantification.<\/span><\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738357,"guid":"76885D006E0911E9B6950997FED07152","previous_id":738356,"previous_guid":"51B6DB506E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"52A47926CBC3479ABC1ECF2531E19280","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"7F1920141B3D43F38D7F9F91CFB07662","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Baseline glucocorticoid use<\/span><span>: <\/span><\/div><div class = \"text-block\">{Y, N, NA}<\/div><div class = \"text-block\">The rationale underlying this variable is to give some indication as to if patients who were on steroids are systematically different in terms of response (or any other variable of interest) compared to those who were not. <\/div><div class = \"text-block\">The OCTAVE trials employed essentially stable glucocorticoid dosing during the induction phase (Table 3, page 40 of the supplemental protocol) at a max entry dose of 25mg prednisone\/9mg budesonide, and mandatory tapering (Table 2, page 646) during the maintenance phase. IV and rectal corticosteroids were prohibited from use over the course of the trial.<\/div><div class = \"text-block\"><span>However, since patients in routine clinical practice are regularly on these co-therapies and do not follow protocolized tapering schedules, this variable will simply <\/span><span style = \":UNDERLINE;\">capture all patients who received any systemic glucocorticoid (including Prednisone, Prednisolone, Budesonide) either intravenously or orally at the time of Tofacitinib initiation<\/span><span>. We are not including rectal steroids here because of generally low systemic absorption unlikely to significantly confound the likelihood of declaring treatment failure or follow-up Mayo score.<\/span><\/div><div class = \"text-block\">Use the clinic or consult note just before and after initiation on the drug as well as communication via phone or email during this period as the source of your data. If the data does not exist in a satisfactory way, record NA.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738358,"guid":"774C22306E0911E9B6950997FED07152","previous_id":738357,"previous_guid":"76885D006E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"BD3752ABC77243DF9149E599B1961990","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"9ADAEABA453F4A739CF2AF763783F266","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Previous treatment with TNF antagonist<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{Y, N, NA}<\/div><div class = \"text-block\"><span>Use the clinic notes, <\/span><span style = \"font-style:italic;\">Care Everywhere<\/span><span> GI notes if they exist, and the \u201cmagnifying glass\u201d global search functionality to determine if the patient has previously received any of the following TNF inhibitors -- Infliximab, Adalimumab, Golimumab, Certolizumab -- specifically for the purposes of treating IBD (e.g. not for a rheumatological or dermatological disorder). <\/span><\/div><div class = \"text-block\">Score as Y if the patient has previously been treated with a TNF antagonist<\/div><div class = \"text-block\">Score as N if patient has never previously been treated with a TNF antagonist<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738359,"guid":"87F56C406E0911E9B6950997FED07152","previous_id":738358,"previous_guid":"774C22306E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"2C1C3875822F4218AA12518995F1B499","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"0675E554EECF44D5B523E9A3E2B52575","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">History of TNF antagonist failure<\/span><span>: <\/span><\/div><div class = \"text-block\">{Y, N, NA}<\/div><div class = \"text-block\"><span>Use the clinic notes, <\/span><span style = \"font-style:italic;\">Care Everywhere<\/span><span> GI notes if they exist, and the \u201cmagnifying glass\u201d global search functionality to determine if the patient has failed any of the following TNF inhibitors -- Infliximab, Adalimumab, Golimumab, Certolizumab -- specifically for the purposes of treating IBD (e.g. not for a rheumatological or dermatological disorder). <\/span><\/div><div class = \"text-block\">As in the OCTAVE protocol and accompanying NEJM publication, the history of treatment failure is as determined by the treating clinician. For Tofacitinib, the trial withdrawal criteria included serious infections, significant abnormal labs, adverse events, surgery, new therapy for UC, or at the patient\u2019s request.<\/div><div class = \"text-block\">Score as Y if the patient has previously failed treatment with a TNF antagonist<\/div><div class = \"text-block\">Score as N if patient has never previously failed treatment with a TNF antagonist<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738360,"guid":"88C195E06E0911E9B6950997FED07152","previous_id":738359,"previous_guid":"87F56C406E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"E62C8657857944908D947B61947A5A76","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"0264F82E6BEE4B0F9B2AC636B9B1A902","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">History of oral glucocorticoid failure<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{Y, N, NA}<\/div><div class = \"text-block\"><span>Use the clinic notes, <\/span><span style = \"font-style:italic;\">Care Everywhere<\/span><span> GI notes if they exist, and the \u201cmagnifying glass\u201d global search functionality to determine if the patient has failed any oral glucocorticoid (e.g. budesonide, prednisone, prednisolone). <\/span><span style = \":UNDERLINE;\">If a patient has been hospitalized for an IBD flare and receives IV steroids (e.g. methylprednisolone) then score this as 1<\/span><span>. <\/span><\/div><div class = \"text-block\">Refer to the section History of TNF antagonist failure for additional guidance. <\/div><div class = \"text-block\">Score as 0 if patient has never previously failed treatment with a Glucocorticoid<\/div><div class = \"text-block\">Score as 1 if the patient has previously failed treatment with a Glucocorticoid<\/div><div class = \"text-block\">There may be a questions raised in this section related to patients receiving lower than typical doses of prednisone, having a partial response to therapy, or responding but in the setting of simultaneous immunosuppressant co-therapy (so difficult to tell which was responsible for the improvement). In general would tend to err on the side of no failure rather than coding this as NA (esp if not unambiguous documented as such).<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738361,"guid":"8AA152606E0911E9B6950997FED07152","previous_id":738360,"previous_guid":"88C195E06E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"42F7E21A157F4C03A542DEDA47E02FB7","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"8E2D22B0E94143328787517919C3DA13","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">History of immunosuppressant failure<\/span><span>: <\/span><\/div><div class = \"text-block\">{Y, N, NA}<\/div><div class = \"text-block\"><span>Use the clinic notes, <\/span><span style = \"font-style:italic;\">Care Everywhere<\/span><span> GI notes if they exist, the presence of thiopurine metabolite laboratories (e.g. 6-Thioguanine), and the \u201cmagnifying glass\u201d global search functionality to determine if the patient has failed any \u2018immunosuppressant\u2019 (e.g. Azathioprine, 6-Mercaptopurine, Methotrexate, Cyclosporine A, Tacrolimus). <\/span><\/div><div class = \"text-block\">Refer to the section History of TNF antagonist failure for additional guidance. <\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">If the patient was previously on this drug in combination with another (e.g. biologic) and was deemed to have failed that regimen, score as Y<\/span><span style = \":UNDERLINE;\">.<\/span><\/div><div class = \"text-block\">Score as Y if the patient has previously failed treatment with an Immunosuppressant<\/div><div class = \"text-block\">Score as N if patient has never previously failed treatment with an Immunosuppressant<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738363,"guid":"CC7BB0906E0911E9B6950997FED07152","previous_id":738347,"previous_guid":"A8E76BD06DF311E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"AA77C3F75BE44E61AC5A43FD9657EB44","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"EA5A8F35430441159D92C6703DED9321","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Follow-up c-reactive protein<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{Rational number, NA}<\/div><div class = \"text-block\"><span>As with the Mayo Endoscopic subscore, use <\/span><span style = \":UNDERLINE;\">the latest available<\/span><span> C-Reactive Protein within the 6-12 month window following Tofacitinib initiation. If it is unavailable strictly within this window, score as NA. If the lab result is reported under the quantifiable limit, report \u20180\u2019. If it is over the quantifiable limit, report the threshold of quantification. <\/span><\/div><div class = \"text-block\"><span style = \":UNDERLINE;\">Be careful that different labs use different units<\/span><span>! We want mg\/L, not mg\/dL.<\/span><\/div><div class = \"text-block\">If the patient is on any glucocorticoid at the time this assessment is done, it\u2019s okay to report whatever was found here (as opposed to mark as \u2018NA\u2019); we are separately assessing corticosteroid use with a different variable. <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738364,"guid":"CD841FE06E0911E9B6950997FED07152","previous_id":738363,"previous_guid":"CC7BB0906E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"B755AC8A14BE42E38B52AC6754471BB3","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"AECEC4EE30844437B39F3CECF5CE4230","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Follow-up fecal calprotectin<\/span><span>: <\/span><\/div><div class = \"text-block\">{Rational number, NA}<\/div><div class = \"text-block\"><span>As with the Mayo Endoscopic subscore, use <\/span><span style = \":UNDERLINE;\">the latest available<\/span><span> Fecal Calprotectin within the 6-12 month window following Tofacitinib initiation. If it is unavailable strictly within this window, score as NA. If the lab result is reported under the quantifiable limit, report \u20180\u2019. If it is over the quantifiable limit, report the threshold of quantification.<\/span><\/div><div class = \"text-block\">If the patient is on any glucocorticoid at the time this assessment is done, it\u2019s okay to report whatever was found here (as opposed to mark as \u2018NA\u2019); we are separately assessing corticosteroid use with a different variable. <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738365,"guid":"CE94F3A06E0911E9B6950997FED07152","previous_id":738364,"previous_guid":"CD841FE06E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"BE925525356A4E15B442881285DF30CD","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"C5B9737F1F504264BE84220E70B3175B","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Follow-up glucocorticoid use<\/span><span>: <\/span><\/div><div class = \"text-block\">{0, 1, NA}<\/div><div class = \"text-block\">Even though this data point does not exist within the clinical trials, it is an important measurement to capture in order to properly interpret the follow-up subscore data.<\/div><div class = \"text-block\">The rationale underlying this variable is to give some indication as to if patients who were on steroids are systematically different in terms of response (or any other variable of interest) compared to those who were not. <\/div><div class = \"text-block\">The OCTAVE trials employed essentially stable glucocorticoid dosing during the induction phase (Table 3, page 40 of the supplemental protocol) at a max entry dose of 25mg prednisone\/9mg budesonide, and mandatory tapering (Table 2, page 646) during the maintenance phase. IV and rectal corticosteroids were prohibited from use over the course of the trial.<\/div><div class = \"text-block\"><span>However, since patients in routine clinical practice are regularly on these co-therapies and do not follow protocolized tapering schedules, this variable will simply <\/span><span style = \":UNDERLINE;\">capture all patients who received any systemic glucocorticoid (including Prednisone, Prednisolone, Budesonide) either intravenously or orally at the time of follow-up<\/span><span>. We are not including rectal steroids here because of generally low systemic absorption unlikely to significantly confound the likelihood of declaring treatment failure or follow-up Mayo score.<\/span><\/div><div class = \"text-block\">Use the clinic or consult note just before and after initiation on the drug as well as communication via phone or email during this period as the source of your data. If the data does not exist in a satisfactory way, record NA.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":738366,"guid":"EC8215A06E0911E9B6950997FED07152","previous_id":738365,"previous_guid":"CE94F3A06E0911E9B6950997FED07152","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"E12DD55CA7D0421A95893677DB77521D","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Effectiveness Spreadsheet"}},{"id":1054724,"guid":"5472741A14FF4EBEBBF7D4208DFF2E73","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Other co-therapy<\/span><span style = \"font-weight:bold;\">:<\/span><\/div><div class = \"text-block\">{0, 1, NA}<\/div><div class = \"text-block\">This is intended to be an indicator variable for whether or not the patient is on any other concurrent therapy that would be expected to positively confound the treatment effect of tofacitinib (e.g. golimumab, vedolizumab, steroid enemas, 5-ASA, hyperbaric oxygen, VSL #3, curcumin). <\/div><div class = \"text-block\">Mark this as 1 if the patient is on any other IBD treatments that might be expected to mask the isolated effect of Tofacitinib from a treatment standpoint. Do not include treatments that treat other non-IBD conditions (e.g. PPI). If the patient is on an immunomodulator with systemic action based on prescription by another provider (e.g. rheumatologist) mark this field as \u20181\u2019 only if this agent has been shown in prospective clinical trials to reduce gastrointestinal inflammation, 0 otherwise.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0},{"id":742238,"guid":"3D584750775211E9950C2D1F0043C634","previous_id":738293,"previous_guid":"5FD29C806DE411E995CCE1C53F573BF9","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"013EA7C6F27A4C96904948E6DE1B36C5","order_id":1,"type_id":6,"title":"Section","source":{"title":"Ulcerative Colitis Table 1 Spreadsheet"}},{"id":1054724,"guid":"BD8786A3BDDD420CA53A54DBD9CA1472","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Disease duration at time of Tofacitinib initiation (# months\/12)<\/span><span>: <\/span><\/div><div class = \"text-block\">{Rational Number, NA}<\/div><div class = \"text-block\">This field requires a greater degree of precision than the prior field assessing age. If chart review does not yield an exact day, use the earliest compatible day at which treatment could have been started. For instance if the patient writes an email indicating that he started treatment about 2 weeks prior to that date of communication, use 14d prior to that date.<\/div><div class = \"text-block\">Then, calculate disease duration in fractional units of years based on dividing the number of months with disease by 12. In other words, if the patient had the disease for 8 years and 3 months, reports 8 + 3\/12 here. This should be reported as a rational number (if using Excel, it should calculate this for you if you use the \u2018=\u2019 prefix).<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"duration":0}],"materials":[],"description":"<div class = \"text-blocks\"><div class = \"text-block\">The \"efficacy-effectiveness gap\" refers to the difference between the treatment efficacy as measured by randomized controlled trials (RCTs) and treatment effectiveness as measured in \"real world\" clinical settings. Prior studies have documented the existance of this gap in a variety of clinical contexts and attributed its existence to a number of factors, including overly restrictive subject inclusion\/exclusion criteria in RCTs and differences in treatment efficacy ascertainment.<\/div><div class = \"text-block\"><span>In this protocol and statistical analysis plan, we document a protocol for a forthcoming study relevant to assessing the efficacy-effectiveness gap of the medication <\/span><span style = \"font-style:italic;\">Tofacitinib<\/span><span> as used to treat Ulcerative Colitis. Specifically, we detail the following:<\/span><\/div><div class = \"text-block\">1) What covariates are needed to compare the real-world effectiveness of Tofacitinib with its efficacy as measured by pivotal clinical trials<\/div><div class = \"text-block\">2) What approach we propose to extract these covariates from the electronic health records at our institution in a relatively reproducible fashion, balancing accuracy with practicality.<\/div><div class = \"text-block\">3) How we propose to analyze the data<\/div><\/div>","changed_on":1558576264}